Marta Castiglia

HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions.

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.

Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines.

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Liquid biopsies in lung cancer: the new ambrosia of researchers.

Cancer and the microbiome: potential applications as new tumor biomarker.

Improvement in lung cancer outcomes with targeted therapies: an update for family physicians.

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?

Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?

A headlight on liquid biopsies: a challenging tool for breast cancer management.

Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.

Dietary restriction: could it be considered as speed bump on tumor progression road?

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?